

Robert Blum
CEO of Cytokinetics
Best podcasts with Robert Blum
Ranked by the Snipd community

May 10, 2024 • 21min
Making waves in cardiovascular disease treatment
Robert Blum, CEO of Cytokinetics, discusses the company's aficamten, cardiac myosin inhibitor, and potential treatments for cardiovascular diseases. They cover aficamten's administration, path to commercialization, impact on patients, and future applications. The conversation also explores CK-136 and omecamtiv mecarbil as innovative pharmacological approaches in cardiac muscle activation for heart health.